← Leaderboards
Jason S Lewis
Sloan-Kettering Inst Can Research
$26,024,327
Attributed
$41,616,806
Total exposure
23
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$41,865,806 · 24
By mechanism
R01$21,082,759 · 8
R35$8,153,426 · 1
P30$4,067,622 · 2
U01$3,484,029 · 1
T32$1,919,365 · 1
P50$1,106,214 · 3
Top collaborators
- Brian Matthew Zeglis10 shared
- Michael John Evans9 shared
- Gabriela Chiosis5 shared
- Mark P. Dunphy5 shared
- Monica L Guzman5 shared
- Yelena Y Janjigian5 shared
- Michael H. Overholtzer5 shared
- Gary Allan Ulaner5 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Jan Grimm$17,140,928
- Govind Ragupathi$973,788
- Yelena Y Janjigian$1,716,445
- Gabriela Chiosis$23,584,161
- Mark P. Dunphy$3,061,237
Others in their field
Top investigators on “Image”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$332,241,999
- Leonard Freedman · Leidos Biomedical Research, Inc.$321,574,964
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$217,904,052
- Ethan Schreier · Associated Universities, Inc.$206,468,864
Research focus
ImageLabelMalignant NeoplasmsBaseMolecular ImagingRadiochemistryProgramsClinical TrialsPre-ClinicalPositron-Emission TomographyMolecularDiagnosisCancer BiologyTumorMemorial Sloan-Kettering Cancer CenterInvestigationClinicRadiolabeledChemistryTissuesResponseClinical TranslationTranslatingUptake
Grant awards (97)
Annotating Cancer Biology through Non-Invasive Molecular Imaging$1,077,600
R35 · FY2025 · CA · contact PI
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin$695,700
R01 · FY2025 · CA · contact PI
Molecular Imaging in Cancer Biology Training Program$470,375
T32 · FY2025 · CA · contact PI
Annotating Cancer Biology through Non-Invasive Molecular Imaging$140,902
R35 · FY2025 · CA · contact PI
Developmental Research Program$127,219
P50 · FY2025 · CA · contact PI
Annotating Cancer Biology through Non-Invasive Molecular Imaging$1,023,720
R35 · FY2024 · CA · contact PI
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin$660,915
R01 · FY2024 · CA · contact PI
Molecular Imaging in Cancer Biology Training Program$401,161
T32 · FY2024 · CA · contact PI
Radiochemistry and Molecular Imaging Probes$364,195
P30 · FY2024 · CA · contact PI
Leveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate Cancer$132,994
R35 · FY2024 · CA · contact PI
Developmental Research Program$115,046
P50 · FY2024 · CA · contact PI
Annotating Cancer Biology through Non-Invasive Molecular Imaging$1,056,048
R35 · FY2023 · CA · contact PI
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin$678,920
R01 · FY2023 · CA · contact PI
Radiochemistry and Molecular Imaging Probes$370,870
P30 · FY2023 · CA · contact PI
Molecular Imaging in Cancer Biology Training Program$203,906
T32 · FY2023 · CA · contact PI
Developmental Research Program$110,771
P50 · FY2023 · CA · contact PI
Annotating Cancer Biology through Non-Invasive Molecular Imaging$1,056,048
R35 · FY2022 · CA · contact PI
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin$692,343
R01 · FY2022 · CA · contact PI
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer$688,387
U01 · FY2022 · CA · contact PI
Molecular Imaging in Cancer Biology Training Program$432,412
T32 · FY2022 · CA · contact PI
Radiochemistry and Molecular Imaging Probes$370,870
P30 · FY2022 · CA · contact PI
Developmental Research Program$123,458
P50 · FY2022 · CA · contact PI
Annotating Cancer Biology through Non-Invasive Molecular Imaging$1,077,600
R35 · FY2021 · CA · contact PI
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin$705,012
R01 · FY2021 · CA · contact PI
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer$689,177
U01 · FY2021 · CA · contact PI
Molecular Imaging in Cancer Biology Training Program$411,511
T32 · FY2021 · CA · contact PI
Radiochemistry and Molecular Imaging Probes$370,870
P30 · FY2021 · CA · contact PI
Annotating Cancer Biology through Non-Invasive Molecular Imaging$143,676
R35 · FY2021 · CA · contact PI
Annotating Cancer Biology through Non-Invasive Molecular Imaging$82,087
R35 · FY2021 · CA · contact PI
Annotating Cancer Biology through Non-Invasive Molecular Imaging$1,062,000
R35 · FY2020 · CA · contact PI
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer$702,430
U01 · FY2020 · CA · contact PI
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$684,004
R01 · FY2020 · CA · contact PI
Radiochemistry and Molecular Imaging Probes$370,870
P30 · FY2020 · CA · contact PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zrrovalpituzumab, a DLL3-targeting monoclonal antibody$367,402
R01 · FY2020 · CA
Annotating Cancer Biology through Non-Invasive Molecular Imaging$141,064
R35 · FY2020 · CA · contact PI
Annotating Cancer Biology through Non-Invasive Molecular Imaging$82,087
R35 · FY2020 · CA · contact PI
Annotating Cancer Biology through Non-Invasive Molecular Imaging$1,077,600
R35 · FY2019 · CA · contact PI
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer$706,245
U01 · FY2019 · CA · contact PI
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$679,482
R01 · FY2019 · CA · contact PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zr-rovalpituzumab, a DLL3-targeting monoclonal antibody$630,572
R01 · FY2019 · CA
Histopathologic validation of 89Zr-DFO-HuMab-5B1 PET/CT imaging in CA 19-9 positive pancreatic cancer$398,509
R01 · FY2019 · CA
Radiochemistry and Molecular Imaging Probes$370,022
P30 · FY2019 · CA · contact PI
Developmental Program$160,624
U54 · FY2019 · CA · contact PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zr-rovalpituzumab, a DLL3-targeting monoclonal antibody$699,927
R01 · FY2018 · CA
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer$697,790
U01 · FY2018 · CA · contact PI
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$674,466
R01 · FY2018 · CA · contact PI
Histopathologic validation of 89Zr-DFO-HuMab-5B1 PET/CT imaging in CA 19-9 positive pancreatic cancer$392,764
R01 · FY2018 · CA
Radiochemisty$357,994
P30 · FY2018 · CA · contact PI
Imaging VEGFR-1 in early metastatic lesions$175,079
R21 · FY2018 · CA · contact PI
Developmental Program$161,044
U54 · FY2018 · CA · contact PI
Radiochemisty$21,115
P30 · FY2018 · CA · contact PI
Radiochemisty$13,274
P30 · FY2018 · CA · contact PI
Radiochemisty$4,924
P30 · FY2018 · CA · contact PI
Radiochemisty$2,734
P30 · FY2018 · CA · contact PI
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$667,617
R01 · FY2017 · CA · contact PI
Biomarkers for predicting response to Hsp90 therapy$572,232
R01 · FY2017 · CA
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$563,930
R01 · FY2017 · CA · contact PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zr-rovalpituzumab, a DLL3-targeting monoclonal antibody$446,668
R01 · FY2017 · CA
Radiochemisty$375,901
P30 · FY2017 · CA · contact PI
Imaging VEGFR-1 in early metastatic lesions$229,436
R21 · FY2017 · CA · contact PI
Bifunctional ligand development for targeted Positron Emission Tomography (PET) using Zirconium-89$179,688
R21 · FY2017 · CA · contact PI
Developmental Program$161,075
U54 · FY2017 · CA · contact PI
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$15,013
R01 · FY2017 · CA · contact PI
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$685,217
R01 · FY2016 · CA · contact PI
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$631,257
R01 · FY2016 · CA · contact PI
Biomarkers for predicting response to Hsp90 therapy$573,509
R01 · FY2016 · CA
Radiochemisty$357,996
P30 · FY2016 · CA · contact PI
Bifunctional ligand development for targeted Positron Emission Tomography (PET) using Zirconium-89$161,344
R21 · FY2016 · CA · contact PI
Developmental Program$160,388
U54 · FY2016 · CA · contact PI
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$67,007
R01 · FY2016 · CA · contact PI
Biomarkers for predicting response to Hsp90 therapy$599,324
R01 · FY2015 · CA
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$566,741
R01 · FY2015 · CA · contact PI
Radiochemisty$357,991
P30 · FY2015 · CA · contact PI
Developmental Program$157,713
U54 · FY2015 · CA · contact PI
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$67,007
R01 · FY2015 · CA · contact PI
World Molecular Imaging Congress 2015: Precision Medicine Visualized$8,000
R13 · FY2015 · CA · contact PI
Biomarkers for predicting response to Hsp90 therapy$550,587
R01 · FY2014 · CA
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$541,423
R01 · FY2014 · CA · contact PI
Radiochemisty$357,996
P30 · FY2014 · CA · contact PI
Cyclotron Radiochemistry and Chemistry$209,401
P50 · FY2014 · CA · contact PI
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$51,996
R01 · FY2014 · CA · contact PI
Novel Adjuvant Discovery in Vaccine Therapy$819,424
R01 · FY2013 · AI · contact PI
Biomarkers for predicting response to Hsp90 therapy$582,268
R01 · FY2013 · CA
Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET$548,810
R01 · FY2013 · CA · contact PI
PET Imaging of Cancer with pH (Low) Insertion Peptide (pHLIP)$459,225
R01 · FY2013 · CA · contact PI
Cyclotron Radiochemistry and Chemistry$217,104
P50 · FY2013 · CA · contact PI
Novel Adjuvant Discovery in Vaccine Therapy$871,728
R01 · FY2012 · AI · contact PI
PET Imaging of Cancer with pH (Low) Insertion Peptide (pHLIP)$549,660
R01 · FY2012 · CA · contact PI
Cyclotron Radiochemistry and Chemistry$203,215
P50 · FY2012 · CA · contact PI
Novel Adjuvant Discovery in Vaccine Therapy$869,286
R01 · FY2011 · AI · contact PI
PET Imaging of Cancer with pH (Low) Insertion Peptide (pHLIP)$472,174
R01 · FY2011 · CA · contact PI
Novel Adjuvant Discovery in Vaccine Therapy$862,703
R01 · FY2010 · AI · contact PI
PET Imaging of Cancer with pH (Low) Insertion Peptide (pHLIP)$487,937
R01 · FY2010 · CA · contact PI
Beta Imager 2000Z Digital Imaging System$249,000
S10 · FY2005 · RR
DIGITAL IMAGING SYST: CANCER$99,600
S10 · FY2005 · RR
DIGITAL IMAGING SYST: PULMONARY MEDICINE, LUNG INJURY$74,700
S10 · FY2005 · RR
DIGITAL IMAGING SYST: NEUROLOGY$74,700
S10 · FY2005 · RR